Solmaz Sahebjam, MD
Researcher

Solmaz Sahebjam, MD

Academic Rank: Assistant Member

Overview

Dr. Sahebjam's research has focused on investigating new promising treatment strategies in brain tumors.

Discipline

    • Neuro-Oncology
    • Chemical Biology and Molecular Medicine Program

Education & Training

    • McGill University, Canada, Fellow - Medical Oncology
    • Shriner's Hospital, McGill University, Postdoctoral Research Fellow - Research Fellowship
    • Iran University of Medical Sciences, Tehran, Iran, MD
    • Lincoln Medical Center/Saint Vincent Hospital, Resident/Intern - Internal Medicine
    • University of Ottawa, Canada, Fellow - Internal Medicine
    • Princess Margaret Hospital/University of Toronto, Research Fellow - New Drug Development, Neuro-Oncology
Research

Dr. Sahebjam has been involved in the development of several clinical trials evaluating the efficacy of immunotherapy in the treatment of brain tumors.  She is also working on new drugs with potential to cross the blood brain barrier and treat cancer.  She is also interested in studying the measures which can improve the quality of life of patients diagnosed with brain cancer.

Publications

  • Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL, Latek R, Zwirtes R, Strauss L, Paliwal P, Harbison CT, Reardon DA, Sampsonc JH. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase 1 cohorts of CheckMate 143. Neurooncol. 2017 Oct. Pubmedid: 29106665.
  • Sahebjam S, Sharabi A, Lim M, Kesarwani P, Chinnaiyan P. Immunotherapy and radiation in glioblastoma. J Neurooncol. 2017 May. Pubmedid: 28567588.
  • Ahmed KA, Kim S, Arrington J, Naghavi AO, Dilling TJ, Creelan BC, Antonia SJ, Caudell JJ, Harrison LB, Sahebjam S, Gray JE, Etame AB, Johnstone PA, Yu M, Perez BA. Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. J Neurooncol. 2017 Jun;133(2):331-338. Pubmedid: 28466250.
  • Groshev A, Padalia D, Patel S, Garcia-Getting R, Sahebjam S, Forsyth PA, Vrionis FD, Etame AB. Clinical outcomes from maximum-safe resection of primary and metastatic brain tumors using awake craniotomy. Clin Neurol Neurosurg. 2017 Jun;157:25-30. Pubmedid: 28384595.
  • Sahebjam S, Forsyth PA, Smalley KS, Tran ND. Experimental Treatments for Leptomeningeal Metastases From Solid Malignancies. Cancer Control. 2017 Jan;24(1):42-46. Pubmedid: 28178711.
  • Ellingson BM, Harris RJ, Woodworth DC, Leu K, Zaw O, Mason WP, Sahebjam S, Abrey LE, Aftab DT, Schwab GM, Hessel C, Lai A, Nghiemphu PL, Pope WB, Wen PY, Cloughesy TF. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials. Neurooncol. 2017 Jan;19(1):89-98. Pubmedid: 27580889. Pmcid: PMC5193027.
  • Sahebjam S, Stallworth DG, Mokhtari S, Tran ND, Arrington JA. Assessing Response of High-Grade Gliomas to Immune Checkpoint Inhibitors. Cancer Control. 2017 Apr;24(2):180-186. Pubmedid: 28441372.
  • Smalley KS, Fedorenko IV, Kenchappa R, Sahebjam S, Forsyth PA. Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy. Int J Cancer. 2016 Sep;139(6):1195-1201. Pubmedid: 27084046. Pmcid: PMC4939138.
  • Fedorenko IV, Evernden B, Kenchappa RS, Sahebjam S, Ryzhova E, Puskas J, McIntosh L, Caceres G, Magliocco A, Etame A, Harbour JW, Smalley KS, Forsyth PA. A rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature. Melanoma Res. 2016 Oct;26(5):481-486. Pubmedid: 27285292. Pmcid: PMC5502096.
  • Ahmed KA, Abuodeh YA, Echevarria MI, Arrington JA, Stallworth DG, Hogue C, Naghavi AO, Kim S, Kim Y, Patel BG, Sarangkasiri S, Johnstone PA, Sahebjam S, Khushalani NI, Forsyth PA, Harrison LB, Yu M, Etame AB, Caudell JJ. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. Ann Oncol. 2016 Dec;27(12):2288-2294. Pubmedid: 27637745.
  • Ahmed KA, Sarangkasiri S, Chinnaiyan P, Sahebjam S, Yu HH, Etame AB, Rao NG. Outcomes Following Hypofractionated Stereotactic Radiotherapy in the Management of Brain Metastases. Am J Clin Oncol. 2016 Aug;39(4):379-383. Pubmedid: 24755663.
  • Gounder MM, Nayak L, Sahebjam S, Muzikansky A, Sanchez AJ, Desideri S, Ye X, Ivy SP, Nabors LB, Prados M, Grossman S, DeAngelis LM, Wen PY. Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors. J Clin Oncol. 2015 Oct;33(28):3186-3192. Pubmedid: 26282642. Pmcid: PMC4857195.
  • Sahebjam S, Garoufalis E, Guiot MC, Muanza T, Del Maestro R, Petrecca K, Sharma R, Kavan P. Bevacizumab use for recurrent high-grade glioma at McGill University Hospital. Can J Neurol Sci. 2013 Mar;40(2):241-246. Pubmedid: 23419575.
  • McNamara MG, Sahebjam S, Mason WP. Anaplastic oligodendroglioma: advances and treatment options. Curr Treat Options Neurol. 2013 Jun;15(3):289-301. Pubmedid: 23344797.
  • Sahebjam S, Siu LL, Razak AA. The utility of hedgehog signaling pathway inhibition for cancer. Oncologist. 2013 Apr;17(8):1090-1099. Pubmedid: 22851551. Pmcid: PMC3425527.
  • Sahebjam S, McNamara M, Mason WP. Management of glioblastoma in the elderly. Clin Adv Hematol Oncol. 2012 Jun;10(6):379-386. Pubmedid: 22895239.
  • Sahebjam S, Aloyz R, Pilavdzic D, Brisson ML, Ferrario C, Bouganim N, Cohen V, Miller WH, Panasci LC. Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score. Br J Cancer. 2011 Oct;105(9):1342-1345. Pubmedid: 21970880. Pmcid: PMC3241562.
  • Atmuri V, Martin DC, Hemming R, Gutsol A, Byers S, Sahebjam S, Thliveris JA, Mort JS, Carmona E, Anderson JE, Dakshinamurti S, Triggs-Raine B. Hyaluronidase 3 (HYAL3) knockout mice do not display evidence of hyaluronan accumulation. Matrix Biol. 2009 Jun;27(8):653-660. Pubmedid: 18762256.
  • Sahebjam S, Khokha R, Mort JS. Increased collagen and aggrecan degradation with age in the joints of Timp3(-/-) mice. Arthritis Rheum. 2007 Mar;56(3):905-909. Pubmedid: 17328064.
  • Land C, Rauch F, Munns CF, Sahebjam S, Glorieux FH. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone. 2006 Oct;39(4):901-906. Pubmedid: 16730480.
  • Mahmoodi M, Sahebjam S, Smookler D, Khokha R, Mort JS. Lack of tissue inhibitor of metalloproteinases-3 results in an enhanced inflammatory response in antigen-induced arthritis. Am J Pathol. 2005 Jun;166(6):1733-1740. Pubmedid: 15920158. Pmcid: PMC1602404.
  • Najmabadi H, Cucci RA, Sahebjam S, Kouchakian N, Farhadi M, Kahrizi K, Arzhangi S, Daneshmandan N, Javan K, Smith RJ. GJB2 mutations in Iranians with autosomal recessive non-syndromic sensorineural hearing loss. Hum Mutat. 2002 May;19(5):572. Pubmedid: 11968091.
  • Najmabadi H, Karimi-Nejad R, Sahebjam S, Pourfarzad F, Teimourian S, Sahebjam F, Amirizadeh N, Karimi-Nejad MH. The beta-thalassemia mutation spectrum in the Iranian population. Hemoglobin. 2001 Aug;25(3):285-296. Pubmedid: 11570721.